Meet A Company Creating Diagnostic Solutions to Enhance Lung Cancer Treatment And Care

Photo by the National Cancer Institute on Unsplash

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Ron Andrews, president, and CEO of OncoCyte Corp. OCX was a guest speaker at Benzinga’s All Access on Jan. 21, 2022.

He discussed his journey out of retirement to join Oncocyte, a molecular diagnostics company aiming to provide revolutionary lung cancer diagnostic solutions and actionable answers throughout critical decision points during lung cancer treatment and care.

Watch the full interview here:

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechPenny StocksGeneralOncoCytePartner Content
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...